Ajit Chande

Dr. Ajit Chande

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2015 in Nature
Verified
Journal Article
Closed access
PDF file
ARAnnachiara Rosa
Annachiara Rosa
ACAjit Chande
Ajit Chande
SZSerena Ziglio
Serena Ziglio
VSVeronica De Sanctis
Veronica De Sanctis
RBRoberto Bertorelli
Roberto Bertorelli
MPMassimo Pizzato
Massimo Pizzato

7 June 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ADAmit Dutt
Amit Dutt
ARAlex H. Ramos
Alex H. Ramos
PHPeter S. Hammerman
Peter S. Hammerman
CMCraig Mermel
Craig Mermel
JCJeonghee Cho
Jeonghee Cho
MMMatthew Meyerson
Matthew Meyerson
Squamous cell lung carcinomas account for approximately 25% of new lung carcinoma cases and 40,000 deaths per year in the United States. Although there are multiple genomically targeted therapies for lung adenocarcinoma, none has yet been reported in squamous cell lung carcinoma. Using SNP array analysis, we found that a region of chromosome segment 8p11-12 containing three genes–WHSC1L1, LETM2, and FGFR1–is amplified in 3% of lung adenocarcinomas and 21% of squamous cell lung carcinomas. Furthermore, we demonstrated that a non-small cell lung carcinoma cell line harboring focal amplification of FGFR1 is dependent on FGFR1 activity for cell growth, as treatment of this cell line either with FGFR1-specific shRNAs or with FGFR small molecule enzymatic inhibitors leads to cell growth inhibition. These studies show that FGFR1 amplification is common in squamous cell lung cancer, and that FGFR1 may represent a promising therapeutic target in non-small cell lung cancer.

1 April 2017 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
CSChetan Sood
Chetan Sood
MMMariana Marin
Mariana Marin
ACAjit Chande
Ajit Chande
MPMassimo Pizzato
Massimo Pizzato
Gregory MelikyanGregory Melikyan
Gregory Melikyan
The host proteins, SERINC3 and SERINC5, have been recently shown to incorporate into HIV-1 particles and compromise their ability to fuse with target cells, an effect that is antagonized by the viral Nef protein. Envelope (Env) glycoproteins from different HIV-1 isolates exhibit a broad range of sensitivity to SERINC-mediated restriction, and the mechanism by which SERINCs interfere with HIV-1 fusion remains unclear. Here, we show that incorporation of SERINC5 into virions in the absence of Nef inhibits the formation of small fusion pores between viruses and cells. Strikingly, we found that SERINC5 promotes spontaneous functional inactivation of sensitive but not resistant Env glycoproteins. Although SERINC5-Env interaction was not detected by co-immunoprecipitation, incorporation of this protein enhanced the exposure of the conserved gp41 domains and sensitized the virus to neutralizing antibodies and gp41-derived inhibitory peptides. These results imply that SERINC5 restricts HIV-1 fusion at a step prior to small pore formation by selectively inactivating sensitive Env glycoproteins, likely through altering their conformation. The increased HIV-1 sensitivity to anti-gp41 antibodies and peptides suggests that SER5 also delays refolding of the remaining fusion-competent Env trimers.

24 November 2020 in Journal of Biosciences
Verified
Journal Article
Closed access
PDF file
MSM Sreepadmanabh
M Sreepadmanabh
ASAmit Kumar Sahu
Amit Kumar Sahu
ACAjit Chande
Ajit Chande

15 November 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
ACAjit Chande
Ajit Chande
ECEmilia Cristiana Cuccurullo
Emilia Cristiana Cuccurullo
ARAnnachiara Rosa
Annachiara Rosa
SZSerena Ziglio
Serena Ziglio
SCSusan Carpenter
Susan Carpenter
MPMassimo Pizzato
Massimo Pizzato
Significance: Serine incorporators (SERINC) 5 and 3 are recently discovered cellular inhibitors of retroviruses, which are incorporated into virus particles and impair their ability to propagate the infection to target cells. Only two groups of viruses (represented by HIV-1 and murine leukemia virus) had been identified as having evolved the ability to counteract SERINC inhibition. We found that equine infectious anemia virus, which causes a debilitating disease in horses, also has acquired the capacity to protect the virus particle from inhibition by SERINC5 and SERINC3 by using its small protein S2. That three different retroviruses have independently evolved the ability to elude inhibition by SERINC5 and SERINC3 indicates that these cellular factors play a fundamental role against various retrovirus pathogens.

1 August 2011 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
WBWritoban Basu Ball
Writoban Basu Ball
SKSusanta Kar
Susanta Kar
MMMadhuchhanda Mukherjee
Madhuchhanda Mukherjee
ACAjit Chande
Ajit Chande
RMRobin Mukhopadhyaya
Robin Mukhopadhyaya
PDPijush K. Das
Pijush K. Das
To reside and multiply successfully within the host macrophages, Leishmania parasites impair the generation of reactive oxygen species (ROS), which are a major host defense mechanism against any invading pathogen. Mitochondrial uncoupling proteins are associated with mitochondrial ROS generation, which is the major contributor of total cellular ROS generation. In the present study we have demonstrated that Leishmania donovani infection is associated with strong upregulation of uncoupling protein 2 (UCP2), a negative regulator of mitochondrial ROS generation located at the inner membrane of mitochondria. Functional knockdown of macrophage UCP2 by small interfering RNA-mediated silencing was associated with increased mitochondrial ROS generation, lower parasite survival, and induction of marked proinflammatory cytokine response. Induction of proinflammatory cytokine response in UCP2 knocked-down cells was a direct consequence of p38 and ERK1/2 MAPK activation, which resulted from ROS-mediated inhibition of protein tyrosine phosphatases (PTPs). Administration of ROS quencher, N-acetyl-l-cysteine, abrogated PTP inhibition in UCP2 knocked-down infected cells, implying a role of ROS in inactivating PTP. Short hairpin RNA-mediated in vivo silencing of UCP2 resulted in decreased Src homology 2 domain-containing tyrosine phosphatase 1 and PTP-1B activity and host-protective proinflammatory cytokine response resulting in effective parasite clearance. To our knowledge, this study, for the first time, reveals the induction of host UCP2 expression during Leishmania infection to downregulate mitochondrial ROS generation, thereby possibly preventing ROS-mediated PTP inactivation to suppress macrophage defense mechanisms.